Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study.

[1]  T. Delozier,et al.  Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. , 2017, European journal of cancer.

[2]  F. Peccatori,et al.  Mechanisms of chemotherapy-induced ovarian damage in breast cancer patients. , 2017, Critical reviews in oncology/hematology.

[3]  P. Barrière,et al.  Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy. , 2017, European journal of cancer.

[4]  C. Villarreal-Garza,et al.  Real-world outcomes in young women with breast cancer treated with neoadjuvant chemotherapy , 2016, Breast Cancer Research and Treatment.

[5]  A. Moini,et al.  Assisted reproductive outcomes in women with different polycystic ovary syndrome phenotypes: the predictive value of anti-Müllerian hormone. , 2016, Reproductive biomedicine online.

[6]  A. Valachis,et al.  Risk of chemotherapy-induced amenorrhea in patients with breast cancer: a systematic review and meta-analysis , 2016, Acta oncologica.

[7]  E. Bar-Meir,et al.  Second international consensus guidelines for breast cancer in young women (BCY2). , 2014, Breast.

[8]  V. Turan,et al.  Failure of Ovarian Suppression With Gonadotropin-Releasing Hormone Analogs to Preserve Fertility: An Assessment Based on the Quality of Evidence. , 2016, JAMA oncology.

[9]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[10]  K. Oktay,et al.  Estimates of young breast cancer survivors at risk for infertility in the U.S. , 2014, The Oncologist.

[11]  R. Tamimi,et al.  Prospective study of fertility concerns and preservation strategies in young women with breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. Su,et al.  What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis , 2014, Breast Cancer Research and Treatment.

[13]  N. Pavlidis,et al.  Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Beckmann,et al.  Participation in the SUCCESS-A Trial Improves Intensity and Quality of Care for Patients with Primary Breast Cancer. , 2013, Geburtshilfe und Frauenheilkunde.

[15]  N. Knowlton,et al.  Correlation of ovarian reserve tests with histologically determined primordial follicle number. , 2011, Fertility and sterility.

[16]  J. Gray,et al.  Fertility and reproductive considerations in premenopausal patients with breast cancer. , 2010, Cancer control : journal of the Moffitt Cancer Center.

[17]  A. Juul,et al.  Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. , 2010, Fertility and sterility.

[18]  M. Ferin,et al.  Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy , 2010, Cancer.

[19]  A. DeMichele,et al.  Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive‐aged breast cancer survivors , 2010, Cancer.

[20]  K. Oktay,et al.  Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. , 2008, Fertility and sterility.

[21]  E. Winer,et al.  Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer , 2008 .

[22]  K. Blackwell,et al.  A Pilot Study of Predictive Markers of Chemotherapy-Related Amenorrhea Among Premenopausal Women with Early Stage Breast Cancer , 2008, Cancer investigation.

[23]  D. Cameron,et al.  The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. , 2006, Human reproduction.

[24]  K. Oktay,et al.  Measuring the impact of chemotherapy on fertility in women with breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Zhang Xue-hong.  Anti-müllerian hormone and ovarian function , 2006 .

[26]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[27]  R. Fanchin,et al.  Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. , 2003, Human reproduction.

[28]  F. Broekmans,et al.  Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. , 2002, Human reproduction.

[29]  M. Cobleigh,et al.  Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Gwyn McClelland.  Survivors , 1891, The Hospital.